
New ASH Myelofibrosis Guidelines: Key Points for Nurses and APPs
A guideline panelist explains expanded molecular testing, early transplant referral, anemia strategies, and symptom-driven JAK inhibitor use.
New American Society of Hematology (ASH) guidelines recommend extended molecular testing at diagnosis, early transplant consultation for higher-risk patients even when they respond to a JAK inhibitor, scenario-specific anemia management, and JAK inhibitor decisions driven by symptoms rather than risk category alone. The 10 recommendations, published in Blood Advances, are all conditional, and the panel noted that important evidence gaps remain.1,2
Guideline panel member Douglas Tremblay, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, New York, discussed the recommendations with Oncology Nursing News.
Why did ASH develop myelofibrosis guidelines?
Up to 6 per 100,000 people are living with myelofibrosis, and because the disease is rare and progressive, treatment can vary substantially among clinicians.1
"Because myelofibrosis is rare and because it is so complex and presentation could be heterogeneous, there is a challenge when seeing a patient with myelofibrosis, particularly in community centers, about what the optimal therapy is," Tremblay said.
What does extended molecular testing involve?
The guidelines favor extended genetic testing, such as next-generation sequencing (NGS), over limited testing for the driver mutations JAK2, CALR, and MPL, at diagnosis and at later decision points.2
"There are certain driver mutations in myelofibrosis, but outside of that, there are other abnormalities that can be seen on next generation sequencing panel that are prognostically important and can impact risk stratification that informs the role of bone marrow transplants in these patients," he said.
Why refer responding patients for transplant consultation?
For higher-risk patients responding to a JAK inhibitor, the panel favors early allogeneic transplant consultation over waiting until response fails.2
"We've learned over the years that even patients who have a good response to myelofibrosis-directed therapies will still be at risk of losing that response or progressing," Tremblay said. "None of the current JAK inhibitors really make a difference in terms of disease progression and transformation to more advanced versions of the disease, like MPN accelerated or blast phase, like acute myeloid leukemia."
Transplant is the only potentially curative treatment, and the workup can take months.1 "The guideline panel is very intentional to suggest early referral for allogeneic stem cell transplant consultation in order to kind of get a head start and not be behind the ball if transplant's needed later on," Tremblay said.
How should nurses approach anemia?
For JAK inhibitor–naive patients whose primary concern is disease-related anemia, the guidelines suggest momelotinib (Ojjaara) or pacritinib (Vonjo), or a non–JAK inhibitor option such as erythropoiesis-stimulating agents (ESAs), luspatercept-aamt (Reblozyl), or danazol.2
When anemia stems from ruxolitinib (Jakafi) or fedratinib (Inrebic), the guidelines split into 2 scenarios:2
- Adequate spleen and symptom control: continue the JAK inhibitor and add anemia-optimization strategies.
- Anemia preventing an optimal dose: switch to momelotinib or pacritinib.
"We broke this up very intentionally in order to address these different scenarios," Tremblay said.
Timing matters as well: early-onset anemia is often drug related, whereas late-onset anemia may signal progression.2
Should symptoms or risk guide JAK inhibitor decisions?
The guidelines support a JAK inhibitor for lower-risk patients with symptomatic splenomegaly or disease-related symptoms and advise against starting one in higher-risk patients without them.2
"There is a tendency to view the treatment of myelofibrosis based on risk status and not based on spleen and symptoms when thinking about JAK inhibitors," Tremblay said. He recommended validated tools such as the MPN Symptom Assessment Form.
"Even if that doesn't show up on a zero to 10 scale, that can often lead to a decision whether or not to initiate a JAK inhibitor to try to counteract some symptoms that may still interfere with someone's daily living," he said.
The guidelines also suggest low-dose aspirin for patients with the JAK2 V617F mutation and advise against routine iron chelation and pretransplant JAK inhibitors in most patients.2
What are the key takeaways for oncology nurses?
- Explain that NGS looks beyond JAK2, CALR, and MPL to refine risk and transplant planning.
- Start transplant conversations early, even when a JAK inhibitor is working.
- Track anemia onset, hemoglobin, and transfusion needs.
- Assess symptoms at baseline and over time with a validated tool.
- Support shared decisions, including aspirin use in patients with JAK2 V617F.
References
- ASH issues new recommendations to improve myelofibrosis care. News release. American Society of Hematology. October 14, 2026. Accessed November 13, 2026.
https://www.hematology.org/newsroom - Stein BL, Abdallah MM, Abel GA, et al. American Society of Hematology 2026 guidelines for the management of myelofibrosis in adults. Blood Adv. Published online October 14, 2026. doi:10.1182/bloodadvances.2026021650
- Pelosci A. Anemia protocol does not reduce ruxolitinib efficacy in myelofibrosis. Oncology Nursing News. June 20, 2025. Accessed November 13, 2026.
https://www.oncnursingnews.com/view/anemia-protocol-does-not-reduce-ruxolitinib-efficacy-in-myelofibrosis
Related to this article








